Following BMS And Abbott
Lilly Taps Iconix's Platform Of 'Drug Signature' Research
By Randall Osborne
Friday, November 18, 2005
Iconix Pharmaceuticals Inc.'s chemogenomics platform bagged another big-name pharma deal, this time signing up Eli Lilly and Co. to a research and license agreement described as "similar in scope" to last year's pacts with Bristol-Myers Squibb Co. and Abbott Laboratories Inc. (BioWorld Today)
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5476
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.